Mirati Therapeutics (NASDAQ:MRTX) Downgraded by Leerink Partnrs
Leerink Partnrs downgraded shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from an outperform rating to a market perform rating in a research report sent to investors on Tuesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Mirati Therapeutics’ Q4 2023 earnings at ($2.24) EPS, FY2023 earnings at ($10.86) EPS, FY2024 earnings at ($9.25) […]
More Stories
Take Charge of My Heart: Release Date, Trailer, Plot, and More
Are you also hunting for the next Korean romantic-comedy drama? Then your search ends here. Take Charge of My Heart...
Minerva Academy: Release Date, Plot, Cast, Trailer, and More
Netflix’s latest Italian drama Minerva Academy is currently streaming online on the popular streaming network Netflix. Its original title is...
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...